<DOC>
	<DOC>NCT00720265</DOC>
	<brief_summary>To prove non-inferiority of MR4 to Prograf by evaluating the efficacy and safety of Prograf and MR4 in new kidney transplant recipients</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient must receive first oral dose of randomized study drug 2days(min 1day) prior to transplant procedure Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment Patient has previously received an organ transplant other than a kidney Patient has received a Kidney transplant from nonheart beating donor or a cadaveric donor Patients has received an ABO incompatible donor kidney Recipient or donor is known to be seropositive for human immunodeficiency virus(HIV) Patient has a current malignancy or a history of malignancy (within the past 5 years), except nonmetastatic basal or squamous cell carcinoma of the skin that has been treated successfully Patient has significant liver, disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site Patient has an uncontrolled concomitant infection(including Hepatitis B, Hepatitis C)or any other unstable medical condition that could interfere with the study objectives Patient is currently taking or has been taking an immunosuppressive agents in the 30 days prior to transplant(except from two days prior to transplant) Patient has a known hypersensitivity to tacrolimus Patient is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Organ Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>FK506MR</keyword>
</DOC>